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We’ve made a good start but substantial challenges remain
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The race to develop a vaccine against Zika began in February
2016, when the unusual clustering of cases of microcephaly and
other neurological disorders associated with Zika virus infection
led to the declaration of a public health emergency of
international concern. When the World Health Organization
held its first consultation in March, 14 active vaccine projects
had already been announced.1 Today, WHO’s pipeline tracker
counts about 30 active projects, pursued by developers from
endemic and non-endemic countries, private and public sector.2
Such a jump start in vaccine development is rare, and several
candidates have already progressed to clinical development.
This pace is facilitated by our collective experience in
developing vaccines against flaviviruses, the availability of
novel vaccine technologies that greatly facilitate manufacturing
of vaccines appropriate for trials in humans, and generous
funding from some governments to support both basic research
and product development.
However, there is no guarantee that the pace we have seen in
early development will continue for the clinical evaluation of
vaccine candidates, nor that the technical feasibility of
developing a vaccine will ultimately result in products capable
of effectively protecting the public. To overcome such
difficulties WHO established the Research and Development
Blueprint for Action to Prevent Epidemics.3 This framework
sets out to guide the preclinical and clinical development of
vaccines, diagnostics, and therapeutics for various priority
diseases, including Zika.3 The blueprint builds on lessons learnt
from the Ebola epidemic, where substantial delays occurred as
stakeholders sought consensus on the best path forwards and
tried to establish the necessary agreements. It aims to minimise
delays and uncertainty. Providing guidance on development of
Zika vaccine candidates is the first test of this blueprint.
At the March 2016 consultation, WHO proposed that priority
should be given to developing vaccines to protect women from
developing Zika disease during pregnancy, which could prevent
microcephaly and related pathologies in newborn infants. In the
following months WHO, Unicef, and other partners developed
a target product profile (TPP) for Zika vaccines for use in an
emergency context.4 The TPP describes the minimal and
preferred characteristics of a product destined for a specific
public health purpose. Although it is not a regulatory document,
it describes performance characteristics that are both
technologically achievable and able to fulfil a public health
function. The aim of the TPP is not to narrow the scope of
scientific work but to direct the scientific, regulatory, and public
health communities to priority characteristics.
Developing the TPP for Zika vaccine was challenging, mostly
because we have a limited understanding of the epidemiology
of the infection and the relative importance of different routes
of transmission. Safety is paramount because the priority target
group is women of childbearing age and some women may
already be pregnant when vaccinated. Pregnancy has
repercussions for most suitable vaccine technologies. The TPP
may be revised as our understanding of the epidemiology,
disease, and disease modulating factors evolves.
Regulatory implications exist for all new vaccines, especially
if they build on technologies that are not used in existing
“routine” vaccines, and it’s still too early to identify a definitive
regulatory strategy for any new Zika vaccine. A continuous
dialogue is needed between developers, regulators, and public
health professionals to identify how best to achieve rapid, robust,
safe, and evidence based licensing.
The design of trials testing new Zika vaccines, including choice
of outcomes, is another key consideration.WHO has established
a process to develop generic annotated trial protocols for priority
diseases,5 including Zika.
Although the WHO blueprint provides a framework for
identifying what a Zika vaccine should aim to achieve, and
establishing mechanisms and partnerships to test candidate
vaccines, WHO is not directly involved in the development of
vaccine candidates. This is being done by various public and
private entities, most notably in the US, Brazil, and India. The
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recently set up Coalition for Epidemic Preparedness Innovations
(www.cepi.net), a new alliance to finance and coordinate the
development of new vaccines to prevent epidemics, might also
be well placed to participate.
Should a future Zika vaccine be used only during outbreaks to
protect women of childbearing age and their babies, or should
it be incorporated in routine vaccination programmes?Wewon’t
know the answer until we have more detailed information on
the evolving epidemiology of the virus, the risk and scale of
neurological outcomes, and the level of herd immunity induced
by a first wave of infection. Development of a Zika vaccine
started well, but all players need to keep up the momentum if
a vaccine is to become a reality within the next three to five
years.
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